

Human Anti-Human CCR4 (Mogamulizumab) Monoclonal Antibody, clone KW-0761 [Biosimilar] (CABT-Z630H)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Biosimilar Recombinant Human Monoclonal Antibody
Specificity	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4).
Immunogen	Humanization of mouse anti-CCR4 mAb7.
Isotype	IgG1, κ
Source/Host	Human
Species Reactivity	Human
Clone	KW-0761
Purification	Protein A or G purified
Conjugate	Functional Grade
Applications	Depletion, ELISA, FA, FC Recommended concentration: FC: ≤ 0.25 µg per 10^6 cells in a volume of 100 µl.
Format	Liquid
Concentration	Lot specific
Size	200 µg

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221

Buffer	0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. Endotoxin Level ≤ 1.0 EU/mg as determined by the LAL method
Preservative	None
Storage	Functional grade biosimilar antibodies may be stored sterile as received at 2-8℃ for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80℃. Avoid Repeated Freeze Thaw Cycles.
Ship	Wet ice

BACKGROUND

Introduction	CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL). Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4. CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.
Keywords	CCR4;chemokine (C-C motif) receptor 4;CKR4;K5-5;CD194;CMKBR4;ChemR13;CC-CKR-4;HGCN:14099;C-C chemokine receptor type 4;CCR-4;C-C CKR-4;chemokine (C-C) receptor 4;Mogamulizumab

GENE INFORMATION

Gene Name	CCR4
Entrez Gene ID	1233
UniProt ID	A0N0Q1

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221